The objective of this study was to identify biologic parameters that were associated with either exceptionally good or poor outcome in childhood acute myeloid leukemia (AML). Among the children with AML who entered Children's Cancer Group trial 213, 498 patients without Down syndrome or acute promyelocytic leukemia (APL) comprise the basis for this report. Univariate comparisons of the proportion of patients attaining complete remission after induction (CR) indicate that, at diagnosis, male gender, low platelet count (р20 000/l), hepatomegaly, myelodysplastic syndrome (MDS), French-AmericanBritish (FAB) category M5, high (Ͼ15%) bone marrow (BM) blasts on day 14 of the first course of induction, and +8 are associated with lower CR rates, while abnormal 16 is associated with a higher CR rate. Multivariate analysis suggests high platelet count at diagnosis (Ͼ20 000/l), absence of hepatomegaly, р15% day 14 BM blast percentage, and abnormal 16 are independent prognostic factors associated with better CR. Univariate analysis demonstrated a significant favorable relationship between platelet count at diagnosis (Ͼ20 000/l), absence of hepatomegaly, low percentage of BM blasts (р15%), and abnormal 16 with overall survival. Absence of hepatomegaly, р15% day 14 BM blast percentage, and abnormal 16 were determined to be independent prognostic factors associated with better survival. Leukemia (2002) 16, 601-607.
Introduction
Analysis of pretreatment characteristics in pediatric acute myeloid leukemia (AML) has been a relatively unrewarding endeavor compared with analysis of pediatric acute lymphocytic leukemia (ALL). In pediatric ALL, the emergence of prognostic factors and their analyses have led to the subdivision of the disease into standard and high risk groups. Treatment for these risk groups differs. 1 In AML, on the other hand, very few factors recognizable at diagnosis or shortly thereafter appear to affect outcome consistently from one study to another. 2 Recently, as therapy has gradually improved, a number of factors have begun to emerge as consistently significant in predicting eventual treatment success. Among these are Down syndrome, white blood cell count (WBC), and possibly French-American-British (FAB) classification and age. [3] [4] [5] [6] [7] In addition, several reports have suggested that cytogenetic abnormalities are also predictive of outcome. 8, 9 In adult AML, (5), del (7), and chromosome 11 abnormalities are unfavorable. [10] [11] [12] [13] Children's Cancer Group (CCG) Study 213 for children and adolescents with acute myeloid leukemia (AML) was open for patient accrual from January 1986 until February 1989. The goals of this study were to improve both the therapy of pediatric AML and expand our knowledge of the effect of pretreatment characteristics on disease outcome. The outcome of the therapy has been described. 14 In this paper, univariate and multivariate methods are used to describe possible relationships between pretreatment characteristics and induction measurements, and obtaining an initial complete remission (CR), or prolonged survival from diagnosis (OS).
Materials and methods

Patients/Diagnosis of AML/Treatment
Patients Ͼ1 month and Ͻ21 years of age with newly diagnosed, previously untreated AML were eligible for the study. Patients with myelodysplastic syndrome (MDS) were only eligible for treatment on this study if they met the criteria for AML. The diagnosis of AML was based on the presence of Ͼ25% abnormal blasts in the bone marrow using Wright's or Wright-Giemsa stains. Other histochemical staining and central review were required, as previously reported.
14 Central nervous system leukemia was diagnosed if five or more white blood cells were seen in the spinal fluid and blasts were identified. The treatment regimen used is outlined in Figure 1 .
Patients
A total of 630 newly diagnosed acute non-lymphocytic leukemia patients was entered from January 1986 until February 1989 (Table 1) . Thirty-eight patients were excluded from the analysis (17 patients 2 years of age or less with AMoL were treated according to a sub-protocol, 20 patients were excluded because institution or central pathology review determined that they did not have AML, and one patient refused to sign the consent form). The current set of 592 patients differs from the set of 591 previously reported 14 due to a change in the number of patients deemed ineligible after
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Figure 1
Schema of CCG-213. Ara-C, cytarabine; L-asp, asparaginase; IT, intrathecal.
review. It has been requested that patients with Down syndrome (n = 35) and patients with acute promyelocytic leukemia (APL) (n = 59) be considered separately. Therefore, a total of 498 patients without Down syndrome or APL form the basis of this report. These 498 patients are referred to as de novo patients in the remainder of the paper to distinguish them from the 94 Down syndrome and APL patients. Informed consent was obtained from each patient, parent, or legal guardian according to institutional policies approved by the Department of Health and Human Services.
Cytogenetics
Cytogenetic studies of the leukemia were required for all patients entering the study. In most cases, the cytogenetic study was performed by the treating institution's cytogenetics laboratory. Two karyotypes were reviewed centrally for adequacy and accuracy by a study cytogenetics subcommittee (DCA, AS, NAH and ML). A minimum of 15 analyzed cells was required for a diagnosis of normal chromosomes. Patients were classified into hierarchical cytogenetic categories. The hierarchical categories are listed in order in Table 2 . For example, the category pseudodiploid contains all pseudodiploid patients without one of the other abnormalities specified above pseudodiploid in Table 2 .
Statistical considerations
Analyses included data obtained in this study up to 13 July 2001. Outcomes of interest were complete response to induction (CR) and overall survival from the time of diagnosis (OS). Univariate analyses of potential prognostic factors compared induction outcomes using Fisher's exact test. Overall survival was evaluated with Kaplan-Meier survival curves and the logrank statistic. 15, 16 Patients lost to follow-up were censored at their last known point of study, with a cut off of 13 February 2001. Corresponding confidence intervals were calculated using Greenwood's formula. 17 Continuous variables were considered using previously defined discrete categories. Factors significant univariately at P Ͻ 0.05 were considered for inclusion in multivariate models. Multivariate models were constructed for induction outcome and survival using stepwise logistic regression and Cox regression, 18 respectively. Forward and backward elimination procedures were employed. The likelihood ratio test was used to determine whether variables should be added or dropped from the multivariate model. Exact logistic regression was used with sparse data. 19 Due to incompleteness of data, separate analyses were performed for patients with cytogenetic data. Multivariate analyses for CR and OS included patients with complete covariate data.
Variables analyzed
Potential prognostic factors considered in the analyses are provided in Tables 1 and 2 . Demographic factors considered include: gender, age and race. In addition, the following clinical characteristics at diagnosis were considered: WBC, hemoglobin level, platelet count, splenomegaly (spleen palpable below the umbilicus), hepatomegaly (liver palpable below the umbilicus), presence of chloroma, central nervous system (CNS) disease, FAB classification, presence of Auer rods, myelodysplastic syndrome (MDS) and karyotype. In addition, the percentage of bone marrow (BM) blasts at day 14 of induction treatment (ie after the first cycle of chemotherapy induction) was considered.
Results
The primary analyses previously reported were repeated using all 592 patients with an additional 7 years of follow-up data.
14 All conclusions and treatment outcome results are consistent. Furthermore, analysis restricted to the 498 de novo patients yielded similar conclusions. Of the 474 de novo patients with available induction outcome data, 364 (76.8%) ended induction in complete remission, 80 (16.9%) failed induction, and 30 (6.3%) were induction deaths. The distribution of causes of death is similar for treatment arms within induction, consolidation and continuation phases on an intent-to-treat or an as-treated basis. Progressive disease (58%), infection (24%), hemorrhage (5%), toxicity (3%) and graft-versus-host disease (3%) are the most common causes of death, comprising 93% of the deaths. With a median follow-up time of 10.8 years, there is no difference in overall survival (P = 0.288) or event-free survival (EFS) (P = 0.473) between the induction therapy groups for the de novo patients when analyzed as intent-to-treat. Overall survival at 7 years for the five-drug followed by the 7 + 3 group and the 7 + 3 followed by the five-drug group is 33 ± 6% and 38 ± 6%, respectively. EFS at 7 years is 27 ± 6% and 29 ± 6% for the respective induction groups. Patients assigned to receive allogeneic bone marrow transplantation (BMT) (n = 96) have OS (P = 0.096) and disease-free survival (DFS) Leukemia (P = 0.130) from the end of induction similar to patients randomized to chemotherapy. At 7 years, OS is 49 ± 10% and 41 ± 6%, while DFS is 41 ± 10% and 34 ± 6% for the BMT and chemotherapy groups, respectively. Although OS (P = 0.310) and DFS (P = 0.353) curves for patients randomized to maintenance therapy after consolidation and patients randomized to stop therapy are similar, survival plateaus for those on the stop therapy arm are higher (OS: 58 ± 10% vs 47 ± 11%; DFS: 50 ± 10% vs 39 ± 11%). As noted previously in our report for the entire study population, 14 results from an as-treated analysis of the de novo patients differ somewhat from the intent-to-treat analysis. Specifically, patients who received BMT have an OS superior to that of patients treated with chemotherapy (P = 0.027). In addition, patients who stopped therapy rather than receiving maintenance therapy have non-significantly better survival (58 ± 10% vs 47 ± 11%, P = 0.157). The Down syndrome patients (n = 35) have a CR rate similar to that of the de novo patients (88% vs 77%, P = 0.194), but have a superior OS (74% vs 35%, P Ͻ 0.001). The APL patients (n = 59) are similar to the de novo patients with respect to CR rate (75% vs 77%, P = 0.737) and OS (41% vs 35%, P = 0.337).
Univariate analyses
As summarized in Table 1 , male gender, hepatomegaly, FAB M5 morphology, presentation with MDS, and day 14 BM with greater than 15% blasts correspond to lower CR rates for de novo patients, while platelet count greater than 20 000/l at diagnosis corresponds to a higher CR rate. Platelets Ͼ20 000/l at diagnosis also are associated with superior survival. Hepatomegaly and day 14 percent BM blasts Ͼ15% are also predictive of inferior survival.
Cytogenetic analysis was accepted after review on 269 of 498 de novo patients (54%). Cytogenetic abnormalities were demonstrated in 192 (71%) of those patients. As indicated in Table 2 , the most common abnormalities found were pseudodiploidy (16%), abnormal 11 (14%), t(8;21) (13%), and +8 (7%). Abnormal 16 patients (n = 17) had a significantly higher CR rate than the other 252 patients with cytogenetic data (100% vs 74%, P = 0.015). The survival experience of the abnormal 16 patients is also better (P = 0.001) than that of the patients with other cytogenetic data (76 ± 20% vs 32 ± 6% OS at 7 years). Patients with +8 (n = 18) tended to achieve CR at a lower rate than patients with other cytogenetic data (56% vs 78%, P = 0.045), but there was not a difference in their survival experiences (P = 0.418).
Multivariate analyses
Multivariate analysis of factors identified in univariate analysis to be associated with either increased or decreased CR rate for all the de novo patients yielded the models summarized in Table 3 . Specifically, platelets greater than 20 000/l at diagnosis is independently predictive of a higher CR rate (2.3 OR, 95% CI: 1.4-3.9), while hepatomegaly (0.6 OR, 95% CI: 0.4-0.9) and day 14 BM with greater than 15% blasts (0.6 Table 3 Multivariate models for CR rate OR, 95% CI: 0.4-0.9) are independently predictive of a poor CR rate. This model implies that a low platelet count at diagnosis and a high day 14 BM blast percentage with hepatomegaly will be predictive of a poor CR rate (47%, 95% CI: 33-62%). Moreover, a high platelet count and a low day 14 BM blast percentage with hepatomegaly is associated with better prognosis: (86%, 95% CI: 81-90%). For de novo patients with cytogenetic data, abnormal 16 was found to be associated with improved OS even after adjusting for platelet count, hepatomegaly, and day 14 BM blast percentage. Specifically, patients with abnormal 16 were found to be 7.2 (95% CI: 1.2-ϱ, P = 0.035) times more likely to achieve remission than patients with other cytogenetic data ( Table 3 ). For all de novo patients, multivariate analysis suggests that presence of hepatomegaly and percent BM blasts at day 14 are independently associated with OS (Table 4) . Patients with hepatomegaly at diagnosis have 1.4 (95% CI: 1.1-1.7, P = 0.005) times greater risk of death than those without hepatomegaly. The risk for those with greater than 15% BM blasts at day 14 is 1.3 (95% CI: 1.0-1.6, P = 0.024) times the risk of patients whose BM blasts at day 14 is р15%. For de novo patients with cytogenetic data, abnormal 16 was found to be associated with improved OS even after adjusting for day 14 BM percentage blast and hepatomegaly. Specifically, patients with abnormal 16 were found to have 0.2 (95% CI: 0.1-0.6, P = 0.004) times less risk of death than patients with other cytogenetic data (Table 4) .
Discussion
This report identifies demographic and clinical factors that are independently prognostic of induction CR rate and OS in childhood AML. Key new findings in this report are the correlation of platelet count less than or equal to 20 000/l at diagnosis with decreased induction remission rate, and hepatomegaly with decreased induction remission rate and OS for de novo patients. Other key findings are the correlation of low day 14 BM blast percentage and abnormal 16 with better CR rate and survival, which have been described by others. 3, 4, 8, 9 In this study, such variables as FAB subtypes, age, and other cytogenetic findings which have been recognized as significant by others did not appear in our multivariate models.
Perhaps some of these differences in prognostic significance of variables are explained by differences in therapy, upon which all prognostic indicators are dependent. If therapy differences do explain whether the variables analyzed are of Leukemia prognostic significance in the various AML studies considered, then therapy modifications probably should not be made on the basis of these variables. In our study, OS was not significantly better for patients receiving BMT relative to those receiving chemotherapy and better for patients not receiving maintenance therapy. Qualitatively, the prognostic factor models summarized in Table 4 appear to hold for the various treatment arms. Disappointingly, with the exception of Down syndrome patients, there does not appear to be a recognizable group of patients for whom current therapy (at the time of this study at least) was adequate. Subsequent CCG studies, however, clearly indicate that for Down syndrome patients, less intensive induction therapy and non-BMT postinduction therapy are clearly superior. 20 This study indirectly supports this finding, in that Down syndrome patients assigned to postinduction chemotherapy had a 90 ± 13% probability of surviving 7 years after achieving remission. Whether patients with inv(16) or patients with FAB M3 (acute promyelocytic leukemia) are in such favorable groups that BMT is not warranted in first remission, remains to be proven.
It is interesting to compare the results of some of the specific cytogenetic findings in this study with those of others. We found an abnormal 16 chromosome (inversion or deletion of chromosome 16) in 17 of 269 (6%) patients with adequate karyotype data, while the St Jude group reported it in 15 of 121 (12%); a more recent Pediatric Oncology Group (POG) study reported it in 28 of 478 (5.9%), and the Sixth International Workshop reported 18/711 (3%), which included predominantly adult cases. 8, 12, 21 Our previous study, CCG 251, which accrued patients from 1979 to 1983, had five of 195 (3%) patients with adequate karyotype with abnormal 16 chromosomes. 9 Our subsequent study, CCG 2891, which ran from 1989 to 1995 had 22 of 313 (7%) with abnormal 16. 22 Our data agreed with the St Jude finding of a 100% CR for these patients and with the International Workshop and POG that their overall survival was superior to that of other patients. Using data from our APL patients, we were unable to confirm the adverse influence of t (15;17) reported by the St Jude group and POG. If anything, our data support a favorable influence of t (15;17) reported in adult studies in the pre-ATRA era. 8, 23 Our findings appear similar to the LAME group, which found that patients with t(15;17) and t(8;21) were similar in outcome to other pediatric patients with AML. 24 We also were unable to confirm the favorable influence of trisomy chromosome 8 on induction success which we had seen in our earlier study, CCG 251. In that trial, 17 of 18 patients achieved a complete remission while in the current study, CCG 213, only nine of 12 patients obtained a CR despite similarities in treatment. 9 More recently, a number of groups, such as the Medical Research Council (MRC), Berlin-Frankfurt-Munster (BFM) and POG, have recommended risk subgroups in pediatric or adult AML based upon combinations of prognostic factors. In these classification systems, patients are assigned to good, standard, and/or poor risk categories based upon a combination of age, sex, initial white blood count, FAB classification, early response (usually day 14-15 marrow status) and cytogenetics. [25] [26] [27] The data in this report support some of the criteria used in these systems (early response, WBC, some FAB criteria and abnormal 16) and offers others (hepatomegaly, platelet count) for inclusion. It also raises concern about the inclusion of some other criteria in an overall favorable prognostic grouping. An example is the grouping of t(8;21) with abnormal 16 into a favorable cytogenetic group. One recent report indicated that t(8:21) was associated with unfavorable survival in pediatric patients, 28 and most pediatric reports, including this one, show neither favorable nor unfavorable outcome for patients with this finding. Inclusion of some standard or even poor risk criteria with other favorable criteria in creating a favorable prognostic grouping may not be enough to counteract the positive effect of the other factors for large groups of patients, but really do the patients with these standard or poor risk features no favor if they subsequently receive less effective therapy than would otherwise be given.
Finally, the limitations of this study should be noted. Despite the relatively large size of the patient population, the size of the subgroups of interest is in many instances quite small, particularly in the various cytogenetic categories. For example, there were only 17 de novo patients with abnormal 16, 35 with t(8;21), and 11 with −7. The small size of these groups severely limits our ability to detect possibly important differences. Additional reports from other studies, which include molecular analyses, are required to clarify these issues.
In summary, this study identified abnormal 16, platelet count at diagnosis and day 14 BM blast percentage as prognostic factors for CR rate in AML patients without Down syndrome. In addition, hepatomegaly, day 14 BM blast percentage and abnormal 16 were identified as prognostic factors for overall survival. Additional studies are required to confirm these findings, enlarge the data set for variables seen with low frequency, and determine if therapy modifications can be recommended on the basis of these findings.
